1. Clinical & Scientific Overview
Apixaban (TIP-MED-000023, Reference Code [3.23]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a Direct Oral Anticoagulant (DOAC); Selective Direct Factor Xa Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.23], p. 32): Eliquis (Pfizer/BMS), Apigat (Nacto/Lupin), Apixabid (Intas), Eliwel (Sun Pharma), Pixaban — Strengths & Dosage Forms: Oral Film-Coated Tablets: 2.5 mg, 5 mg
Oral Film-Coated Tablets: 2.5 mg, 5 mg
3. Mechanism of Action & Pharmacodynamics
Direct Oral Anticoagulant (DOAC); Selective Direct Factor Xa Inhibitor acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Direct Oral Anticoagulant (DOAC); Selective Direct Factor Xa Inhibitor for Stroke and systemic embolism prevention in non-valvular atrial fibrillation (NVAF); treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT/PE; VTE prophylaxis post-elective hip or knee replacement surgery..
4. Therapeutic Indications & Evidence-Supported Uses
- Stroke and systemic embolism prevention in non-valvular atrial fibrillation (NVAF)
- treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT/PE
- VTE prophylaxis post-elective hip or knee replacement surgery
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: NVAF Stroke Prevention: Standard dose 5 mg BD. Reduce to 2.5 mg BD via two distinct criteria: (1) Standard 2-of-3 ABC Criteria (>=2 of: Age >=80 yrs, Body weight <=60 kg, or Serum Creatinine >=1.5 mg/dL), OR (2) Severe Renal Impairment Criterion (Cockcroft-Gault CrCl 15–29 mL/min per Indian/EMA/BNF SmPC). Acute DVT/PE: 10 mg BD x 7d, then 5 mg BD.
Administration & Meal Timing: With or without food (unlike rivaroxaban 15/20 mg, apixaban absorption is ~50% regardless of food). May be crushed and suspended in water/apple juice for nasogastric tube administration. | Strictly twice daily (every 12 hours: e.g., 08:00 AM and 08:00 PM)—missing doses rapidly removes anticoagulation because the half-life is ~12 hours.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Calculate CrCl via Cockcroft-Gault (actual body weight). NVAF: Reduce to 2.5 mg BD if CrCl 15–29 mL/min (independent renal criterion) OR if >=2 of 3 ABC criteria (Age >=80, Wt <=60 kg, SCr >=1.5 mg/dL) are met; avoid if CrCl <15 mL/min. Hepatic: Child-Pugh A: No adjustment; Child-Pugh B: Caution; Child-Pugh C: Contraindicated.
Renal: Calculate CrCl via Cockcroft-Gault (actual body weight). NVAF: Reduce to 2.5 mg BD if CrCl 15–29 mL/min (independent renal criterion) OR if >=2 of 3 ABC criteria (Age >=80, Wt <=60 kg, SCr >=1.5 mg/dL) are met; avoid if CrCl <15 mL/min. Hepatic: Child-Pugh A: No adjustment; Child-Pugh B: Caution; Child-Pugh C: Contraindicated.
Renal: Calculate CrCl via Cockcroft-Gault (actual body weight). NVAF: Reduce to 2.5 mg BD if CrCl 15–29 mL/min (independent renal criterion) OR if >=2 of 3 ABC criteria (Age >=80, Wt <=60 kg, SCr >=1.5 mg/dL) are met; avoid if CrCl <15 mL/min. Hepatic: Child-Pugh A: No adjustment; Child-Pugh B: Caution; Child-Pugh C: Contraindicated.
7. Contraindications, Precautions & High-Risk Warnings
- Strictly contraindicated in mechanical prosthetic heart valves and moderate-to-severe rheumatic mitral stenosis (must use warfarin), active pathological bleeding, and triple-positive antiphospholipid syndrome. Hold 24–48 hours prior to elective surgery depending on bleeding risk and CrCl.
Key Clinical Precautions: Renal: Calculate CrCl via Cockcroft-Gault (actual body weight). NVAF: Reduce to 2.5 mg BD if CrCl 15–29 mL/min (independent renal criterion) OR if >=2 of 3 ABC criteria (Age >=80, Wt <=60 kg, SCr >=1.5 mg/dL) are met; avoid if CrCl <15 mL/min. Hepatic: Child-Pugh A: No adjustment; Child-Pugh B: Caution; Child-Pugh C: Contraindicated.
8. Adverse Effects Profile
- Minor epistaxis, gum bleeding, easy bruising, menorrhagia, mild nausea.
- Major gastrointestinal or intracranial haemorrhage (significantly lower intracranial and GI bleed rates than warfarin in elderly NVAF patients), spinal/epidural haematoma with neuraxial anaesthesia.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Strong dual inhibitors of both CYP3A4 and P-gp (ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir) double apixaban exposure—reduce dose by 50% (or avoid if already on 2
- 5 mg BD)
- Strong CYP3A4/P-gp inducers (rifampicin, carbamazepine, phenytoin) reduce apixaban levels by 50% and cause stroke/thrombosis—avoid combination
- Additive bleeding with aspirin, clopidogrel, NSAIDs, and SSRIs
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Emphasise that unlike warfarin, apixaban does not need monthly INR blood tests or spinach restrictions, but because its effect wears off in 12 hours, skipping even 1 or 2 doses leaves you unprotected against stroke. Never take OTC painkillers (NSAIDs) and report black stools, red urine, or head trauma immediately.
- Meal & Clock Timing Instruction: With or without food (unlike rivaroxaban 15/20 mg, apixaban absorption is ~50% regardless of food). May be crushed and suspended in water/apple juice for nasogastric tube administration. (Strictly twice daily (every 12 hours: e.g., 08:00 AM and 08:00 PM)—missing doses rapidly removes anticoagulation because the half-life is ~12 hours.)
- Missed Dose Protocol: Take the missed dose immediately on the same day if within 6 hours of the scheduled time, then take the evening dose at the normal hour. Never take two tablets at the same time.
- Geriatric Dispensing Pearl: Verify the 'ABC Rule' (Age ≥80 years, Body weight ≤60 kg, Creatinine ≥1.5 mg/dL) in every elderly Indian patient—many frail elderly Indian patients weigh 48–58 kg, so once they turn 80 or their creatinine reaches 1.5 mg/dL, they qualify for the safer 2.5 mg BD dose.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 2.5 mg, 5 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.23] (p. 32)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.25] Nitroglycerin (Glyceryl Trinitrate — GTN) — Organic Nitrate; Nitric Oxide (NO) Donor Venodilator & Coronary V
- [3.26] Cilnidipine — Dual L-Type & N-Type Dihydropyridine Calcium-Channel Blocker (Sch
- [3.27] Nifedipine (Sustained-Release / Osmotic-Release) — Dihydropyridine L-Type Calcium-Channel Blocker (Schedule H | NLEM
- [3.28] Diltiazem Hydrochloride — Non-Dihydropyridine Calcium-Channel Blocker — Benzothiazepine (Sc
